Brazil's Anvisa Approves Kyinsu, Weekly Insulin+Semaglutide Combo Pen for Type 2 Diabetes

Brazil's health regulator Anvisa approved Kyinsu, a once-weekly pen combining basal insulin and semaglutide for adults with type 2 diabetes. This marks a regulatory milestone in diabetes care, potentially improving adherence and outcomes. The market impact is sector-specific, with no immediate macro-directional signal.